O	0	6	Effect
O	7	9	of
O	10	11	6
O	12	18	months
O	19	21	of
B-intervention	22	29	aerobic
I-intervention	30	38	training
O	39	41	on
O	42	52	adipokines
O	53	55	as
O	56	62	breast
O	63	69	cancer
O	70	74	risk
O	75	82	factors
O	83	85	in
O	86	100	postmenopausal
O	101	106	women
O	106	107	:
O	108	109	A
O	110	120	randomized
O	121	131	controlled
O	132	137	trial
O	137	138	.

O	139	147	Physical
O	148	156	activity
O	157	160	has
O	161	165	been
O	166	176	introduced
O	177	179	as
O	180	182	an
O	183	194	inexpensive
O	195	198	and
O	199	208	effective
O	209	217	behavior
O	218	220	to
O	221	227	reduce
O	228	242	postmenopausal
O	243	249	breast
O	250	256	cancer
O	257	261	risk
O	261	262	.

O	263	272	Decreased
O	273	287	concentrations
O	288	290	of
O	291	301	adipokines
O	302	306	such
O	307	309	as
O	310	316	leptin
O	317	320	and
O	321	329	resistin
O	330	333	may
O	334	336	be
O	337	338	a
O	339	347	possible
O	348	357	mechanism
O	357	358	.

O	359	363	This
O	364	369	study
O	370	375	aimed
O	376	378	to
O	379	390	investigate
O	391	394	the
O	395	402	effects
O	403	405	of
O	406	407	6
O	408	414	months
O	415	417	of
O	418	425	aerobic
O	426	434	training
O	435	437	on
O	438	444	leptin
O	445	448	and
O	449	457	resistin
O	458	464	levels
O	465	467	in
O	468	482	postmenopausal
O	483	488	women
O	488	489	.

O	490	493	The
O	494	499	study
O	500	512	participants
O	513	517	were
B-age	518	520	50
I-age	520	521	-
I-age	521	523	74
I-age	524	529	years
O	530	533	old
O	533	534	,
B-eligibility	535	544	sedentary
I-eligibility	545	548	and
I-eligibility	549	563	postmenopausal
I-eligibility	564	569	women
O	569	570	.

B-total-participants	571	576	Forty
I-total-participants	576	577	-
I-total-participants	577	580	one
O	581	586	women
O	587	590	met
O	591	594	the
O	595	604	inclusion
O	605	613	criteria
O	614	617	and
O	618	622	were
O	623	631	randomly
O	632	640	assigned
O	641	643	to
O	644	647	the
O	648	656	training
O	657	658	(
O	658	659	n
O	660	661	=
B-intervention-participants	662	664	22
O	664	665	)
O	666	668	or
O	669	672	the
B-control	673	680	control
I-control	681	686	group
O	687	688	(
O	688	689	n
O	690	691	=
B-control-participants	692	694	19
O	694	695	)
O	695	696	.

O	697	709	Participants
O	710	712	in
O	713	725	intervention
O	726	731	group
O	732	739	engaged
O	740	742	in
O	743	744	a
O	745	753	moderate
O	754	764	supervised
O	765	772	aerobic
O	773	781	training
O	781	782	,
O	783	784	3
O	785	789	days
O	790	793	per
O	794	798	week
O	799	802	for
O	803	804	6
O	805	811	months
O	811	812	,
O	813	818	while
O	819	827	controls
O	828	832	were
O	833	838	asked
O	839	842	not
O	843	845	to
O	846	852	change
O	853	858	their
O	859	867	physical
O	868	876	activity
O	877	883	levels
O	884	887	for
O	888	891	the
O	892	900	duration
O	901	903	of
O	904	907	the
O	908	913	trial
O	913	914	.

O	915	921	Plasma
O	922	936	concentrations
O	937	939	of
O	940	946	leptin
O	947	950	and
O	951	959	resistin
O	959	960	,
O	961	968	aerobic
O	969	976	fitness
O	976	977	,
O	978	981	and
O	982	996	anthropometric
O	997	1005	measures
O	1006	1010	were
O	1011	1019	assessed
O	1020	1022	at
O	1023	1031	baseline
O	1032	1035	and
O	1036	1041	after
O	1042	1043	6
O	1044	1050	months
O	1050	1051	.

B-total-participants	1052	1058	Twenty
I-total-participants	1058	1059	-
I-total-participants	1059	1064	seven
O	1065	1068	out
O	1069	1071	of
O	1072	1074	41
O	1075	1087	participants
O	1088	1097	completed
O	1098	1101	the
O	1102	1107	study
O	1107	1108	.

B-outcome	1109	1115	Plasma
I-outcome	1116	1122	leptin
O	1123	1132	decreased
O	1133	1135	by
O	1136	1137	0
O	1137	1138	.
O	1138	1139	6
O	1139	1140	%
O	1141	1143	in
O	1144	1154	exercisers
O	1155	1158	and
O	1159	1168	increased
O	1169	1171	by
O	1172	1173	8
O	1173	1174	.
O	1174	1175	2
O	1175	1176	%
O	1177	1179	in
O	1180	1188	controls
O	1188	1189	;
O	1190	1197	however
O	1197	1198	,
O	1199	1202	the
O	1203	1211	exercise
O	1212	1218	effect
O	1219	1222	was
O	1223	1226	not
O	1227	1240	statistically
O	1241	1252	significant
O	1252	1253	.

B-outcome	1254	1260	Plasma
I-outcome	1261	1275	concentrations
I-outcome	1276	1278	of
I-outcome	1279	1287	resistin
O	1288	1292	also
O	1293	1302	decreased
O	1303	1305	by
O	1306	1308	16
O	1308	1309	.
O	1309	1310	1
O	1310	1311	%
O	1312	1315	and
O	1316	1318	15
O	1318	1319	.
O	1319	1320	1
O	1320	1321	%
O	1322	1324	in
O	1325	1333	exercise
O	1334	1337	and
O	1338	1345	control
O	1346	1351	group
O	1351	1352	,
O	1353	1365	respectively
O	1365	1366	.

B-outcome	1367	1374	Aerobic
I-outcome	1375	1382	fitness
O	1383	1392	increased
O	1392	1393	,
O	1394	1397	and
B-outcome	1398	1402	body
I-outcome	1403	1407	mass
I-outcome	1408	1413	index
I-outcome	1414	1415	(
I-outcome	1415	1418	BMI
I-outcome	1418	1419	)
O	1420	1429	decreased
O	1430	1443	significantly
O	1444	1446	in
O	1447	1450	the
O	1451	1463	intervention
O	1464	1469	group
O	1469	1470	.

O	1471	1474	The
O	1475	1483	exercise
O	1484	1496	intervention
O	1497	1500	did
O	1501	1504	not
O	1505	1509	have
O	1510	1511	a
O	1512	1525	statistically
O	1526	1537	significant
O	1538	1544	impact
O	1545	1547	on
O	1548	1551	the
B-outcome	1552	1566	concentrations
I-outcome	1567	1569	of
I-outcome	1570	1573	the
I-outcome	1574	1584	adipokines
O	1585	1587	in
O	1588	1596	question
O	1596	1597	;
O	1598	1605	however
O	1605	1606	,
O	1607	1611	this
O	1612	1616	long
O	1616	1617	-
O	1617	1621	term
O	1622	1629	aerobic
O	1630	1638	training
O	1639	1646	reduced
B-outcome	1647	1650	BMI
O	1651	1654	and
B-outcome	1655	1659	body
I-outcome	1660	1663	fat
I-outcome	1664	1674	percentage
O	1675	1678	and
O	1679	1687	enhanced
B-outcome	1688	1695	aerobic
I-outcome	1696	1703	fitness
O	1703	1704	.

O	1705	1709	Thus
O	1709	1710	,
O	1711	1719	exercise
O	1720	1728	programs
O	1729	1732	can
O	1733	1735	be
O	1736	1746	considered
O	1747	1749	as
O	1750	1752	an
O	1753	1762	effective
O	1763	1773	behavioral
O	1774	1786	modification
O	1787	1789	in
O	1790	1796	breast
O	1797	1803	cancer
O	1804	1814	prevention
O	1814	1815	.
